Industry news
-
The Pharma Trends you Need to Know—A CDMO’s Perspective
18 June 2020
The market momentum of novel therapies targeting unmet needs is creating a new landscape for pharmaceutical drug manufacturers. As the focus on these smaller patient pools grows, so does the complexity of drug development.
-
RUB 16 Million Will be Spent on a Clinical Trial for a Russian Coronavirus Vaccine
18 June 2020
The Gamaleya Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation will spend almost 16 million rubles to study a vaccine for the new coronavirus, and then test it on 60 volunteers.
-
COVID-19 Human Vaccine Tests In Singapore To Begin In August
17 June 2020
Singapore scientists testing a COVID-19 vaccine from U.S. firm Arcturus Therapeutics plan to start human trials in August after promising initial responses in mice.
-
Human trials of new coronavirus vaccine are due to begin this week
17 June 2020
Scientists at Imperial College London will start the first clinical trials of a potential COVID-19 vaccine this week with more than 45 million pounds ($56.50 million) in backing from the British government and philanthropic donors.
-
Begins Phase 3 Clinical Trials with Baricitinib for Patients with COVID-19
16 June 2020
Eli Lilly and Company announced that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled study to evaluate the efficacy and safety of baricitinib, an oral JAK1/JAK2 inhibitor licensed from Incyte, in hospitalized adults with COVID-19. Baricitinib, marketed as OLUMIANT®, is approved in 70 countries as a treatment for adults with moderately to severely active rheumatoid arthritis (RA).
-
The First Clinical Trial of a Cocktail of Antibodies for the Treatment of COVID-19
16 June 2020
Regeneron Pharmaceuticals, Inc. announced initiation of the first clinical trial of REGN-COV2, its investigational dual antibody cocktail for the prevention and treatment of COVID-19. The REGN-COV2 clinical program will consist of four separate study populations: hospitalized COVID-19 patients, non-hospitalized symptomatic COVID-19 patients, uninfected people in groups that are at high-risk of exposure (such as healthcare workers or first responders) and uninfected people with close exposure to a COVID-19 patient (such as the patient’s housemate). The placebo-controlled trials will be conducted at multiple sites.
-
The First Batch of the Antiviral Drug Avifavir Delivered to Russian Hospitals
15 June 2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group today announce the delivery of the first batch of Avifavir to Russian hospitals.
-
Production of Russia’s First Coronavirus Vaccine Will Be at the Alium Plant
15 June 2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, Sistema PJSFC and the Gamaleya National Research Institute of Epidemiology and Microbiology have agreed to cooperate to organise a production site at the Alium plant in Zelenograd in the Moscow region, for the large-scale production of the first vaccine for the prevention of coronavirus infection in Russia.
-
Work is in Progress in Spain on Ten Vaccine Projects
11 June 2020
Clinical tests of a vaccine against the novel coronavirus may begin in Spain in the autumn of 2020, Science and Innovation Minister Pedro Duque told TASS in an interview.
-
In Russia They Will Launch Produce Plasma-based Coronavirus Therapy
11 June 2020
The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, announces a partnership with Nacimbio (part of the State Corporation Rostec) to carry out a joint project for the production of a drug for coronavirus therapy based on blood plasma.
